Suggested remit: To appraise the clinical and cost effectiveness of crovalimab within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
Cost Comparison Standard
|
| ID number |
6140
|
Provisional Schedule
| Expected publication |
20 November 2024 |
Project Team
| Project lead |
Louise Jafferally |
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
Roche (crovalimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
PNH Support |
| Professional groups |
National PNH Service |
| |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
Alexion Pharmaceuticals (eculizumab, ravulizumab) (confidentiality agreement signed, participating) |
| |
Novartis (iptacopan) (confidentiality agreement signed, participating) |
| |
Amgen (eculizumab) (confidentiality agreement not signed, not participating) |
| |
Samsung Bioepis (eculizumab) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
26 September 2024 - 10 October 2024
|
Final draft guidance |
|
09 April 2024
|
Invitation to participate |
|
13 September 2023 - 11 October 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6140 |
|
13 October 2022
|
In progress. DHSC referral received |
|
15 June 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual